Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; and HUTCHMED (China) Limited. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2013
Exchange: NASDAQ
Website: epizyme.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2022 | $1.50 | Outperform → Market Perform | Cowen |
| 6/27/2022 | Outperform → Neutral | Wedbush | |
| 3/2/2022 | $15.00 → $10.00 | Buy | HC Wainwright & Co. |
| 8/10/2021 | $10.00 → $5.00 | Equal-Weight → Underweight | Morgan Stanley |
| 8/10/2021 | $36.00 → $15.00 | Buy | HC Wainwright & Co. |
Appointment of Jerald Korn as Chief Operating Officer First Patient Dosed in the Randomized Portion of SYMPHONY-1 (EZH-302), Epizyme's Phase 1b/3 Confirmatory Study of Tazemetostat in Combination with R2 Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced a clinical update as well as the appointment of Jerald Korn as Chief Operating Officer, reporting to President and Chief Executive Officer, Grant Bogle. "We are excited to welcome Jerald to Epizyme at a pivotal time for the organization," said Mr. Bogle. "Jerald's breadth of experienc
MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board. Kazumi brings experience as both an entrepreneur and an investor within the field of biotechnology. She is currently the CEO of Twentyeight-Seven, a biotech company focused on novel RNA biology that she co-founded alongside prominent Harvard investigators. Kazumi was also a co-founder and CEO of Mitobridg
4 - Epizyme, Inc. (0001571498) (Issuer)
4 - Epizyme, Inc. (0001571498) (Issuer)
4 - Epizyme, Inc. (0001571498) (Issuer)
4 - Epizyme, Inc. (0001571498) (Issuer)
4 - Epizyme, Inc. (0001571498) (Issuer)
4 - Epizyme, Inc. (0001571498) (Issuer)
4 - Epizyme, Inc. (0001571498) (Issuer)
4 - Epizyme, Inc. (0001571498) (Issuer)
4 - Epizyme, Inc. (0001571498) (Issuer)
4 - Epizyme, Inc. (0001571498) (Issuer)
Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-5) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 08/13/2024. Application Category: NDA, Application Number: 211723, Application Classification: Labeling
Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-4) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 11/16/2023. Application Category: NDA, Application Number: 211723, Application Classification: Labeling
15-12G - Epizyme, Inc. (0001571498) (Filer)
EFFECT - Epizyme, Inc. (0001571498) (Filer)
EFFECT - Epizyme, Inc. (0001571498) (Filer)
EFFECT - Epizyme, Inc. (0001571498) (Filer)
S-8 POS - Epizyme, Inc. (0001571498) (Filer)
S-8 POS - Epizyme, Inc. (0001571498) (Filer)
POS AM - Epizyme, Inc. (0001571498) (Filer)
S-8 POS - Epizyme, Inc. (0001571498) (Filer)
S-8 POS - Epizyme, Inc. (0001571498) (Filer)
S-8 POS - Epizyme, Inc. (0001571498) (Filer)
Transaction focused on lead asset Tazverik® (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. Acquisition to bolster Ipsen's growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to acquire all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005092/en/ Disclaimer: Intended for international media and investor audiences only Ipsen ((Euronext: IPN, OTC:IPSEY) and Epizyme (NASDAQ:EPZM) today announced that they have entered into a defini
TAZVERIK® (tazemetostat) Net Product Revenue of $8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021 First Patient Dosed in the Randomized Phase 3 Portion of SYMPHONY-1 (EZH-302), Epizyme's Phase 1b/3 Confirmatory Study Assessing Tazemetostat in Combination with R2 in Follicular Lymphoma (FL) Updated Data from the Phase 1b Portion of SYMPHONY-1 to be Presented at ASCO; Additional Updates Anticipated in 2H 2022 from Tazemetostat and EZM0414 (SETD2 inhibitor) Studies Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients again
Epizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference call to discuss its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5369344. A live webcast will be available in the investor section of the company's website at www.epizyme.com, and will be archived for 60 days following the call. About Epizyme, Inc.
Epizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business update on Tuesday, March 1, 2022 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 4082815. A live webcast will be available in the investor section of the company's website at www.epizyme.com, and will be archived for 60 days following the call. About Epizyme, Inc. Epizyme, Inc. is a fully integrat
-- TAZVERIK® (tazemetostat) Net Product Revenues of $5.2 Million; End User Demand Grew 22% -- -- Received $25 Million Upfront Payment from HUTCHMED License Agreement -- -- SYMPHONY-1 (EZH-302) Preparing for Phase 3 Initiation; SETD2 Phase 1/1b Study Initiated -- Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today reported its third quarter 2021 financial results and business update. "I am pleased with the progress we made as an organization in the third quarter against the four pillars of our strategic plan. In terms of TAZVERIK commercial performance, total end user demand grew 22% this quarte
Epizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its third quarter 2021 financial results and provide a business update on Tuesday, November 9, 2021 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 8536979. A live webcast will be available in the investor section of the company's website at www.epizyme.com, and will be archived for 60 days following the call. About Epizyme, Inc. Epizyme, Inc. is a fully integrated, commerci
Current Chief Executive Officer, Robert Bazemore, to Step Down; Current Board Member, Grant Bogle, Named Incoming CEO Epizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies today announced its Chief Executive Officer (CEO) succession plan, with industry veteran Grant Bogle succeeding Robert Bazemore, as President and CEO. Mr. Bazemore will move into an active consultancy role, serving as an advisor to the Company, and in particular to Mr. Bogle, for the next 12 months to ensure a smooth transition. Mr. Bogle will continue to serve as a member of Epizyme's Board of Directors. The succession is effectiv
Total Revenue of $13.0 Million in 2Q 2021; TAZVERIK® Net Product Revenues of $8.0 Million Revised Commercial Strategy and Operating Plan to Accelerate Adoption of TAZVERIK® and Focus Investment on Important Value-Driving Programs IND Clearance for Novel SETD2 Inhibitor, EZM-0414; Clinical Trial Initiation Anticipated in 2H 2021 Strategic Partnership with HutchMed to Bring TAZVERIK® to Patients in Greater China Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today reported its second quarter 2021 financial results and provided a business update. "TAZVERIK has significant potential as a backbone
Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED's novel oncology medicines portfolio Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payments, together with additional tiered royalties; HUTCHMED to receive development and commercial rights to TAZVERIK® in Greater China HUTCHMED to host a webcast and call on Monday August 9, at 9:30 a.m. EDT / 2:30 p.m. BST / 9:30 p.m. HKT – see www.hutch-med.com/event for details HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and CAMBRIDGE, Mass, Aug. 08, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:
Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED's novel oncology medicines portfolio Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payments, together with additional tiered royalties; HUTCHMED to receive development and commercial rights to TAZVERIK® in Greater China HUTCHMED to host a webcast and call on Monday, August 9, at 9:30 a.m. EDT / 2:30 p.m. BST / 9:30 p.m. HKT – see www.hutch-med.com/event for details Epizyme, Inc. ("Epizyme") (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, and HUTCHM
Cowen downgraded Epizyme from Outperform to Market Perform and set a new price target of $1.50
Wedbush downgraded Epizyme from Outperform to Neutral
HC Wainwright & Co. reiterated coverage of Epizyme with a rating of Buy and set a new price target of $10.00 from $15.00 previously
Morgan Stanley downgraded Epizyme from Equal-Weight to Underweight and set a new price target of $5.00 from $10.00 previously
HC Wainwright & Co. reiterated coverage of Epizyme with a rating of Buy and set a new price target of $15.00 from $36.00 previously
Morgan Stanley reiterated coverage of Epizyme with a rating of Equal-Weight and set a new price target of $10.00 from $11.00 previously
SVB Leerink upgraded Epizyme from Market Perform to Outperform and set a new price target of $16.00 from $12.00 previously
Cowen resumed coverage of Epizyme with a rating of Outperform and set a new price target of $14.00
Morgan Stanley reiterated coverage of Epizyme with a rating of Equal-Weight and set a new price target of $11.00 from $14.00 previously
Credit Suisse initiated coverage of Epizyme with a rating of Outperform and set a new price target of $13.00
SC 13G/A - Epizyme, Inc. (0001571498) (Subject)
SC 13D - Epizyme, Inc. (0001571498) (Subject)
SC 13D/A - Epizyme, Inc. (0001571498) (Subject)
SC 13G/A - Epizyme, Inc. (0001571498) (Subject)
SC 13G/A - Epizyme, Inc. (0001571498) (Subject)
SC 13G/A - Epizyme, Inc. (0001571498) (Subject)
SC 13G/A - Epizyme, Inc. (0001571498) (Subject)
SC 13G/A - Epizyme, Inc. (0001571498) (Subject)
SC 13D/A - Epizyme, Inc. (0001571498) (Subject)
SC 13G/A - Epizyme, Inc. (0001571498) (Subject)
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company's Novel, First-in-Class, Oral SETD2 Inhibitor Merger with Ipsen Expected to Close in 3Q 2022 Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update. "I am pleased with the progress we made as an organization in the second quarter. In addition to the growth of TAZVERIK net product
Extension allows for satisfaction of the HSR Condition as outlined in the Merger Agreement Epizyme stockholders are encouraged to tender their shares to the offer today Regulatory News: Ipsen S.A. ((Euronext: IPN, OTC:IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ:EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non-transferable contingent value right (CVR) per Sha
Transaction focused on lead asset Tazverik® (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. Acquisition to bolster Ipsen's growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to acquire all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005092/en/ Disclaimer: Intended for international media and investor audiences only Ipsen ((Euronext: IPN, OTC:IPSEY) and Epizyme (NASDAQ:EPZM) today announced that they have entered into a defini
Updated Activity Data from Phase 1b Portion of the Study Shows Continued Improvement in Both Objective and Complete Response Rates Update Includes Response Data for Sub-Group of Patients Who Are Rituximab-Refractory and with POD24 Epizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, announced updated safety and activity data from the Phase 1b safety run-in portion of its Phase 1b/3 confirmatory study evaluating the investigational use of tazemetostat, a first-in-class, oral, selective inhibitor of EZH2, in combination with rituximab + lenalidomide
Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that Grant Bogle, President and Chief Executive Officer, and Shefali Agarwal, Senior Medical Advisor and Interim Chief Medical and Development Officer, will present at the H.C. Wainwright Global Investment Conference. A pre-recorded fireside chat will be available to play on demand stating at 7:00am EST on Tuesday, May 24, 2022. It can be found in the investor section of the Company's website at www.epizyme.com and will be archived after 60 days following the presentation. About Epizym
TAZVERIK® (tazemetostat) Net Product Revenue of $8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021 First Patient Dosed in the Randomized Phase 3 Portion of SYMPHONY-1 (EZH-302), Epizyme's Phase 1b/3 Confirmatory Study Assessing Tazemetostat in Combination with R2 in Follicular Lymphoma (FL) Updated Data from the Phase 1b Portion of SYMPHONY-1 to be Presented at ASCO; Additional Updates Anticipated in 2H 2022 from Tazemetostat and EZM0414 (SETD2 inhibitor) Studies Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients again
Epizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference call to discuss its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5369344. A live webcast will be available in the investor section of the company's website at www.epizyme.com, and will be archived for 60 days following the call. About Epizyme, Inc.
Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that the Company has granted equity awards to Jerald Korn, the Company's Chief Operating Officer, with a grant date of April 1, 2022, as equity inducement awards outside of the Company's 2013 Stock Incentive Plan and material to Mr. Korn's acceptance of employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Korn received options to purchase an aggregate of 800,000 shares of Epizyme common stock. The options have an exercise pr
Appointment of Jerald Korn as Chief Operating Officer First Patient Dosed in the Randomized Portion of SYMPHONY-1 (EZH-302), Epizyme's Phase 1b/3 Confirmatory Study of Tazemetostat in Combination with R2 Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced a clinical update as well as the appointment of Jerald Korn as Chief Operating Officer, reporting to President and Chief Executive Officer, Grant Bogle. "We are excited to welcome Jerald to Epizyme at a pivotal time for the organization," said Mr. Bogle. "Jerald's breadth of experienc
Epizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today announced its participation in two investor conferences in March. Cowen 42nd Annual Health Care Conference Shefali Agarwal, Chief Medical Officer, will participate in the Cowen 42nd Annual Health Care Conference as part of the Targeted Oncology panel. Tuesday, March 8, at 9:10am EST Barclays Global Healthcare Conference Grant Bogle, Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference. Tuesday, March 15, 2022, at 2:05pm EST Live webcasts of the presentations wi